Skip to main content
Clinical Trials/NCT05819359
NCT05819359
Active, Not Recruiting
Phase 2

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BIA 28-6156 in Subjects With Parkinson's Disease With a Pathogenic Variant in the Glucocerebrosidase (GBA1) Gene

Bial R&D Investments, S.A.95 sites in 3 countries237 target enrollmentMarch 31, 2023

Overview

Phase
Phase 2
Intervention
BIA 28-6156 10 mg
Conditions
Parkinson's Disease
Sponsor
Bial R&D Investments, S.A.
Enrollment
237
Locations
95
Primary Endpoint
Time from baseline to clinically meaningful progression on motor aspects of experiences of daily living (assessed by MDS-UPDRS Part II score and MDS-UPDRS Part III score)
Status
Active, Not Recruiting
Last Updated
4 months ago

Overview

Brief Summary

The purpose of this randomized, double-blind, placebo-controlled study is to assess the efficacy of BIA 28-6156 over placebo in delaying clinical meaningful motor progression over 78 weeks in subjects with Parkinson's disease who have a pathogenic variant in the glucocerebrosidase 1 (GBA1) gene (GBA-PD).

Detailed Description

This is a 2-part (Part A \[Genetic Screening\] and Part B \[Double-Blind Treatment\]), Phase 2, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety, tolerability, pharmacodynamics, and pharmacokinetics of 2 fixed dose levels of BIA 28-6156 (10 and 60 mg/day) in approximately 237 subjects with genetically confirmed GBA-PD. Part A (Genetic Screening) will identify individuals with a PD risk-associated variant in the GBA1 gene for potential enrolment into Part B (Double-Blind Treatment) of the study. Part B will consist of a screening period to ensure that all protocol inclusion/exclusion criteria for Part B of the study are met (up to 5 weeks). After screening period, eligible subjects will be randomized into 1 of 3 treatment arms (BIA 28-6156 10 mg/day, BIA 28-6156 60 mg/day, or placebo) in a 1:1:1 ratio, and enter a double-blind treatment period up to 78 weeks, followed by a 30-day (4 weeks) of safety follow-up period. Subjects must be receiving a stable dose of PD medication for at least 30 days before screening (for Part B \[Double-Blind Treatment\]) and will continue to receive their usual PD medications throughout the study.

Registry
clinicaltrials.gov
Start Date
March 31, 2023
End Date
July 31, 2026
Last Updated
4 months ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Bial R&D Investments, S.A.
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Subjects who satisfy all of the following criteria will be eligible for Part A (Genetic Screening) of the study:
  • The subject is ≥35 and ≤80 years of age at the time of informed consent.
  • The subject has a clinical diagnosis of PD for at least 1 year and for no longer than 7 years before initiation of screening (for Part A), as confirmed by a neurologist using the MDS Criteria for Parkinson's Disease.
  • The subject has a modified Hoehn and Yahr score ≤2.
  • The subject is receiving symptomatic treatment for PD.
  • The subject is capable of giving signed informed consent.
  • Subjects who satisfy all the following criteria will be eligible for Part B (Double-Blind Treatment) of the study:
  • Informed Consent - The subject is capable of giving signed informed consent.
  • The subject has a known GBA-PD risk-associated variant (as determined in Part A \[Genetic Screening\] of this study).
  • The subject has a score ≥22 on the Montreal Cognitive Assessment (MoCA) scale.

Exclusion Criteria

  • Individuals who do not satisfy the inclusion criteria for Part A (Genetic Screening) will be excluded.
  • Subjects who meet any of the following criteria for Part B (Double-Blind Treatment) are not eligible for the study.
  • The subject has Gaucher's disease (GD), as defined by clinical signs and symptoms (i.e., hepatosplenomegaly, cytopenia, skeletal disease), and/or a medical history of marked deficiency of GCase activity compatible with GD.
  • The subject is homozygous for a GBA1 pathogenic variant that is known to be associated with GD or compound heterozygous for 2 alleles that are known to be associated with GD.
  • The subject carries a known PD-associated LRRK2 pathogenic variant.
  • The subject has atypical or secondary parkinsonism by medical history or in the opinion of the investigator. Atypical parkinsonism includes, but is not limited to, diagnoses of progressive supranuclear palsy, cortico-basal syndrome, and multiple system atrophy. Secondary parkinsonism includes drug-induced, toxin-induced, postinfectious, posttraumatic, or vascular parkinsonism.
  • The subject has a history of (within 60 days before initiation of screening) or has planned upcoming major surgery that could interfere with, or for which the treatment might interfere with, the conduct of the study or that would pose an unacceptable risk to the subject in the opinion of the investigator.
  • The subject has any active or chronic disease or condition other than PD that could interfere with, or for which the treatment might interfere with, the conduct of the study or pose an unacceptable risk to the subject in the opinion of the investigator based on medical history, physical examination, vital signs, 12-lead ECG, or clinical laboratory tests. Minor deviations of laboratory values from the normal range may be acceptable if judged by the investigator to have no/minor clinical relevance.
  • The subject has a recent history (last 6 months) of abuse of addictive substances (alcohol, illegal substances), currently uses \>21 units of alcohol per week, or is a regular recreational user of sedatives, hypnotics, tranquillizers, or any other addictive agent in the opinion of the investigator.
  • The subject has a positive test for drugs of abuse at screening or before administration of the first dose of investigational medicinal product (IMP) that the investigator judges as clinically relevant. A positive test for tetrahydrocannabinol (THC) is exclusionary. A positive test for cannabinoids (not containing THC) is not exclusionary if the subject is a recreational user (not an abuser) of cannabinoids, in the opinion of the investigator, and agrees to abstain from using cannabinoids within 12 hours before study visits. A positive drug screen that is attributed to an allowed prescription drug is not exclusionary but should be agreed with the medical monitor.

Arms & Interventions

BIA 28-6156 10 mg

Participants will be randomized to receive BIA 28-6156 10 mg during the Treatment Period.

Intervention: BIA 28-6156 10 mg

BIA 28-6156 60 mg

Participants will be randomized to receive BIA 28-6156 60 mg during the Treatment Period.

Intervention: BIA 28-6156 60 mg

Placebo

Placebo

Intervention: Placebo

Outcomes

Primary Outcomes

Time from baseline to clinically meaningful progression on motor aspects of experiences of daily living (assessed by MDS-UPDRS Part II score and MDS-UPDRS Part III score)

Time Frame: From Baseline up to Week 78

Time from baseline to clinically meaningful progression on motor aspects of experiences of daily living, as assessed by ≥2-point increase from baseline in Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part II score and no improvement in the Motor Examination, as assessed by ≥0-point increase from baseline in MDS-UPDRS Part III score. MDS-UPDRS is a multimodal scale assessing impairment and disability consisting of 4 parts. Part II assesses motor experiences of daily living (Range 0-52). It contains 13 questions which are to be rated by the patient and/or caregiver. Part III assesses the motor signs of PD and is rated by the investigator (Range 0-132). Part III contains 33 scores based on 18 items. For each question a numeric score is assigned between 0-4, where 0 = Normal, 1 = Slight, 2 = Mild, 3 = Moderate, 4 = Severe. A higher score indicates more severe symptoms of PD.

Secondary Outcomes

  • Time from baseline to clinically meaningful progression on motor signs of the disease (assessed by MDS-UPDRS Part III score)(From Baseline up to Week 78)
  • Change from Baseline to Week 78 in the 39-Item Parkinson's Disease Questionnaire (PDQ-39) score(From Baseline up to Week 78)
  • Time from baseline to any worsening on the Patient Global Impression - Change (PGI-C) scale(From Baseline up to Week 78)
  • Change from Baseline to Week 78 in the MDS-UPDRS Total (Part I-IV) score(From Baseline up to Week 78)
  • Change from Baseline to Week 78 in the Modified Hoehn and Yahr score(From Baseline up to Week 78)
  • Time from baseline to any worsening on the Clinical Global Impression - Change (CGI-C) scale(From Baseline up to Week 78)

Study Sites (95)

Loading locations...

Similar Trials

Related News

Bial's Phase 2b ACTIVATE Study Reaches 75% Completion Milestone for GBA1-Associated Parkinson's Disease Treatment- Bial announced that 75% of patients in its Phase 2b ACTIVATE study have completed the double-blind treatment period through week 78, marking a significant milestone toward completion. - The study is evaluating BIA 28-6156, a first-in-class oral allosteric activator of beta-glucocerebrosidase, in 273 genetically confirmed GBA1-associated Parkinson's disease patients across 85 sites in 11 countries. - Topline results are expected in mid-2026, with the potential to deliver the first disease-modifying treatment that directly addresses the underlying cause of GBA1-associated Parkinson's disease. - The study demonstrates strong patient retention despite its complexity, reflecting the substantial unmet medical need for treatments targeting this genetic form of Parkinson's disease that affects 5-15% of all PD patients.Bial's BIA 28-6156 Reaches Key Milestone in Phase 2 Trial for GBA-Associated Parkinson's Disease- Bial's ACTIVATE Phase 2 trial for BIA 28-6156 has enrolled 273 genetically confirmed GBA-PD patients across 85 sites, with over 80% reaching the one-year treatment milestone. - BIA 28-6156 is a first-in-class, once-daily oral allosteric activator of beta-glucocerebrosidase designed to directly modify the underlying cause of GBA-associated Parkinson's disease. - The trial is expected to complete by April 2026 with topline results anticipated in Q2 2026, potentially offering the first disease-modifying treatment for this patient population. - Bial will present research at the upcoming MDS Congress showing that GBA-PD patients experience more severe and rapidly progressing non-motor symptoms compared to sporadic Parkinson's disease.BIAL's BIA 28-6156 Phase 2 Trial Reaches Milestone with First Patient Completion- BIAL announced that the first patient has completed the full dose regimen in the Phase 2 ACTIVATE study of BIA 28-6156 for GBA1-related Parkinson's disease. - BIA 28-6156 is a first-in-class, orally administered, small molecule allosteric activator of beta-glucocerebrosidase (GCase) to modify the disease's underlying cause. - The ACTIVATE study is a multicenter, randomized, double-blind, placebo-controlled trial evaluating the efficacy, safety, and tolerability of BIA 28-6156. - Topline data from the Phase 2 study, which enrolled over 230 patients across 85 sites in Europe and North America, is expected in mid-2026.BIAL Doses First Patient in Phase 2 Trial of BIA 28-6156 for GBA-Related Parkinson's Disease- BIAL R&D has dosed the first patient in the Phase 2 ACTIVATE trial (NCT05819359) to evaluate BIA 28-6156 for Parkinson's disease patients with GBA1 gene mutations. - The ACTIVATE trial is a randomized, double-blind, placebo-controlled study assessing the efficacy, safety, tolerability, pharmacodynamics, and pharmacokinetics of BIA 28-6156 at two fixed dose levels. - BIA 28-6156, an allosteric activator of beta-glucocerebrosidase (GCase), represents a novel approach to potentially delay motor progression in GBA-PD patients. - Phase 1b trial data demonstrated BIA 28-6156's safety and ability to reach pharmacologically active concentrations in plasma and cerebrospinal fluid, with observed intracellular GluCer elevations.BIAL R&D Doses First Patient in Phase 2 Trial of BIA 28-6156 for Parkinson's Disease with GBA1 Mutation- BIAL R&D has dosed the first patient in its Phase 2 ACTIVATE study, evaluating BIA 28-6156 for Parkinson's disease patients with a GBA1 gene mutation. - The ACTIVATE study is a multicenter, randomized, double-blind, placebo-controlled trial assessing the efficacy, safety, and tolerability of BIA 28-6156 at two fixed dose levels. - BIA 28-6156 is a novel allosteric activator of beta-glucocerebrosidase (GCase), designed to enhance enzyme activity and potentially delay motor progression in GBA-PD patients. - The trial will enroll approximately 237 genetically confirmed GBA-PD subjects across sites in North America and Europe, with results expected to inform future treatment strategies.